查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1563846

全球血液檢測市場

Blood Screening
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 158 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計2030年全球血液檢測市場將達38億美元

全球血液檢測市場預計 2023 年為 26 億美元，預計到 2030 年將達到 38 億美元，2023-2030 年分析期間複合年成長率為 5.6%。核酸檢測 (NAT) 是本報告分析的細分市場之一，預計複合年成長率為 5.3%，到分析期結束時將達到 17 億美元。分析期內，酵素結合免疫吸附檢測法(ELISA) 領域的複合年成長率預計為 6.2%。

美國市場預估為6.977億美元，中國預期複合年成長率為9.1%

預計 2023 年美國血液檢測市場規模將達到 6.977 億美元。中國作為世界第二大經濟體，預計2030年市場規模將達到8.314億美元，2023-2030年分析期間複合年成長率為9.1%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 1.9% 和 6.0%。在歐洲，德國的複合年成長率預計為 3.0%。

全球血液檢測市場－主要趨勢與促進因素總結

為什麼血液檢測對於安全醫療保健至關重要？

血液檢測是醫療保健中的一個重要過程，旨在在血液樣本用於輸血、器官移植或診斷目的之前檢測血液樣本中的傳染源、遺傳性疾病和其他健康狀況。這個篩檢過程對於確保血液和血液製品的安全以及預防愛滋病毒、肝炎和梅毒等感染疾病至關重要。血液檢測在癌症、遺傳性遺傳疾病等疾病的早期發現方面也發揮著重要作用，以便及時介入和治療。血液篩檢測試的準確性和可靠性至關重要，因為它們直接影響患者安全和公共健康。隨著全球對安全血液產品的需求持續成長，血液檢測已成為現代醫療保健的重要組成部分，以保護患者並確保治療效果。

科技進步如何改變血液檢測過程？

技術的進步使血液檢測領域更快、更準確、更全面的檢測方法。傳統上，血液檢測依賴於手動技術和基本血清學檢測，這些檢測雖然有效，但範圍有限，可能需要幾天才能得出結果。自動化測試系統和分子診斷的引入極大地提高了血液檢查的速度和準確性。核酸檢測（NAT）等技術可以更早檢測病毒和細菌病原體，從而降低輸血相關感染疾病的風險。此外，高通量篩檢系統的開發可以更有效地處理大量血液樣本，這對於滿足現代醫療機構的需求至關重要。因此，血液檢測技術的進步不僅提高了血液製品的安全性，而且擴大了可檢測的疾病範圍，使其成為預防醫學的基石。

血液檢測技術有哪些新趨勢與創新？

由於需要更全面、更快速、更具成本效益的診斷解決方案，血液檢測目前正在經歷重大創新。最顯著的趨勢之一是次世代定序儀(NGS) 在血液檢測中的使用越來越多。這樣可以對遺傳物質進行詳細分析，並且可以從單一血液樣本中識別出多種病原體和遺傳疾病。另一個新興趨勢是將人工智慧（AI）和機器學習整合到血液檢測過程中，透過識別傳統方法可能遺漏的模式和異常來提高診斷準確性。此外，照護現場(POC) 檢測設備的發展將能夠在各種環境中進行快速檢測，包括偏遠地區和資源有限的地區，從而改善關鍵診斷的獲取，血液檢測也發生了顯著變化。這些創新正在突破血液檢測的極限，提供早期檢測、更個人化的治療選擇和改善患者治療結果的潛力。

推動血液檢測市場擴張的因素有哪些？

血液檢測市場的成長是由幾個關鍵因素推動的，這些因素凸顯了安全、準確的診斷在醫療保健領域日益重要。關鍵促進因素之一是對血液和血液製品的需求不斷成長，特別是在醫療基礎設施不斷擴張的新興市場。隨著手術、輸血和移植的增加，對嚴格的血液檢測以防止感染疾病傳播的需求變得更加迫切。核酸檢測 (NAT) 和次世代定序(NGS) 等技術進步也透過提供更準確、更有效率的篩檢選項來推動市場成長。此外，慢性病盛行率的增加以及對早期檢測和預防性醫療保健的興趣的增加正在推動對全面血液篩檢測試的需求。在政府措施和法規的支持下，全球推動提高公共衛生標準，這進一步推動了血液檢測市場的擴張。這些因素，加上診斷技術的持續創新，凸顯了血液檢測在現代醫療保健中的關鍵作用，確保世界各地患者的安全和福祉。

受訪企業舉例（總合12家）

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols International SA
  • Ortho Clinical Diagnostics, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP10749

Global Blood Screening Market to Reach US$3.8 Billion by 2030

The global market for Blood Screening estimated at US$2.6 Billion in the year 2023, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2023-2030. Nucleic Acid Test (NAT), one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Enzyme-Linked Immunosorbent Assay (ELISA) segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$697.7 Million While China is Forecast to Grow at 9.1% CAGR

The Blood Screening market in the U.S. is estimated at US$697.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$831.4 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.0% CAGR.

Global Blood Screening Market - Key Trends and Drivers Summarized

Why Is Blood Screening Essential in Ensuring Safe Healthcare Practices?

Blood screening is a critical process in healthcare, designed to detect infectious agents, genetic disorders, and other health conditions in blood samples before they are used for transfusions, organ transplants, or diagnostic purposes. This screening process is vital to ensuring that blood and blood products are safe for use, thereby preventing the transmission of diseases such as HIV, hepatitis, and syphilis. Blood screening also plays a crucial role in the early detection of conditions like cancer and inherited genetic disorders, allowing for timely intervention and treatment. The accuracy and reliability of blood screening tests are paramount, as they directly impact patient safety and public health. As the demand for safe blood products continues to rise globally, blood screening has become an indispensable component of modern healthcare, protecting patients and ensuring the efficacy of medical treatments.

How Has the Evolution of Technology Transformed Blood Screening Processes?

The field of blood screening has been revolutionized by advancements in technology, leading to faster, more accurate, and comprehensive testing methods. Traditionally, blood screening relied on manual techniques and basic serological tests, which, while effective, were limited in scope and could take days to yield results. The introduction of automated testing systems and molecular diagnostics has drastically improved the speed and accuracy of blood screening. Techniques such as nucleic acid testing (NAT) allow for the detection of viral and bacterial pathogens at a much earlier stage, reducing the risk of transmitting infections through blood transfusions. Additionally, the development of high-throughput screening systems has enabled the processing of large volumes of blood samples more efficiently, which is crucial in meeting the demands of modern healthcare facilities. As a result, the evolution of blood screening technology has not only enhanced the safety of blood products but has also expanded the range of detectable conditions, making it a cornerstone of preventive healthcare.

What Are the Emerging Trends and Innovations in Blood Screening Technology?

Blood screening is currently undergoing significant innovation, driven by the need for more comprehensive, faster, and cost-effective diagnostic solutions. One of the most notable trends is the growing use of next-generation sequencing (NGS) in blood screening, which allows for the detailed analysis of genetic material and the identification of a wide range of pathogens and genetic disorders from a single blood sample. Another emerging trend is the integration of artificial intelligence (AI) and machine learning into blood screening processes, which enhances the accuracy of diagnostics by identifying patterns and anomalies that might be missed by conventional methods. Furthermore, the development of point-of-care (POC) testing devices is transforming blood screening by enabling rapid testing in various settings, including remote and resource-limited areas, thus improving access to critical diagnostics. These innovations are pushing the boundaries of what is possible in blood screening, offering the potential for earlier detection, more personalized treatment options, and improved patient outcomes.

What Are the Factors Fueling Expansion of the Blood Screening Market?

The growth in the blood screening market is driven by several critical factors that underscore the increasing importance of safe and accurate diagnostics in healthcare. One of the primary drivers is the rising demand for blood and blood products, particularly in emerging markets where healthcare infrastructure is expanding. As more surgeries, transfusions, and transplants are performed, the need for rigorous blood screening to prevent the transmission of infectious diseases is becoming more urgent. Technological advancements, such as the adoption of nucleic acid testing (NAT) and next-generation sequencing (NGS), are also fueling market growth by offering more precise and efficient screening options. Additionally, the increasing prevalence of chronic diseases and the growing focus on early detection and preventive care are boosting the demand for comprehensive blood screening tests. The global push for improved public health standards, supported by government initiatives and regulations, is further driving the expansion of the blood screening market. These factors, combined with ongoing innovations in diagnostic technology, highlight the critical role of blood screening in modern healthcare, ensuring the safety and well-being of patients worldwide.

Select Competitors (Total 12 Featured) -

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche AG
  • Grifols International SA
  • Ortho Clinical Diagnostics, Inc.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Blood Screening - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Safe Blood Donations Throws the Spotlight on Advanced Blood Screening Technologies
    • Increasing Incidence of Bloodborne Diseases Drives Demand for Comprehensive Blood Screening Tests
    • Advancements in Molecular Diagnostics Propel Growth in Rapid and Accurate Blood Screening Solutions
    • Shift Toward Early Disease Detection Expands Addressable Market Opportunity for Blood Screening Innovations
    • Innovations in High-Throughput Screening Accelerate Demand for Efficient Blood Testing Systems
    • Expansion of Point-of-Care Diagnostics Spurs Growth in Portable and Rapid Blood Screening Devices
    • Integration of AI in Diagnostics Drives Adoption of Automated Blood Screening Systems
    • Innovations in Sample Collection and Processing Are Enhancing Blood Screening Accuracy
    • Growing Importance of Infection Control Expands Market Penetration for Comprehensive Blood Screening Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Blood Screening Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Blood Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nucleic Acid Test (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nucleic Acid Test (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Nucleic Acid Test (NAT) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Enzyme-Linked Immunosorbent Assay (ELISA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Rapid Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Rapid Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Rapid Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Western Blot Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Western Blot Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Western Blot Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Next-Generation Sequencing (NGS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Reagents & Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Reagents & Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Blood Banks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Blood Banks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • JAPAN
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • CHINA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • EUROPE
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Blood Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • FRANCE
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • GERMANY
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Blood Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • INDIA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Blood Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Blood Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Blood Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Blood Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030
  • AFRICA
    • Blood Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Blood Screening by Technology - Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Blood Screening by Technology - Percentage Breakdown of Value Sales for Nucleic Acid Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Western Blot Assay and Next-Generation Sequencing (NGS) for the Years 2014, 2024 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Blood Screening by Product & Service - Reagents & Kits, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Blood Screening by Product & Service - Percentage Breakdown of Value Sales for Reagents & Kits, Instruments and Software & Services for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Blood Screening by End-Use - Blood Banks and Hospitals - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Blood Screening by End-Use - Blood Banks and Hospitals Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Blood Screening by End-Use - Percentage Breakdown of Value Sales for Blood Banks and Hospitals for the Years 2014, 2024 & 2030

IV. COMPETITION